What is Raymond James’ Forecast for TSE:MDP Q3 Earnings?

Medexus Pharmaceuticals Inc. (TSE:MDP) – Investment analysts at Raymond James issued their Q3 2025 EPS estimates for Medexus Pharmaceuticals in a report issued on Tuesday, November 19th. Raymond James analyst M. Freeman forecasts that the company will post earnings per share of $0.01 for the quarter. Raymond James currently has a “Outperform” rating and a $4.00 target price on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at $0.01 EPS, FY2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.24 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $0.90 EPS and FY2028 earnings at $0.89 EPS.

Several other equities research analysts also recently weighed in on MDP. Stifel Canada upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Stifel Nicolaus raised their price objective on Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Stock Up 15.0 %

Shares of TSE:MDP opened at C$2.45 on Friday. The firm has a 50 day moving average of C$2.46 and a 200 day moving average of C$2.19. The company has a market capitalization of C$60.10 million, a price-to-earnings ratio of 42.60 and a beta of 1.96. Medexus Pharmaceuticals has a 52 week low of C$1.44 and a 52 week high of C$3.16.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.